Clinical Trial Update: Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC [Phase 3]

View source ↗

Summary

This Phase 3 trial compares re-radiochemotherapy plus pembrolizumab to immuno(chemo)therapy in locoregionally recurrent PD-L1-positive head and neck squamous ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Universität des Saarlandes | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING